https://orcid.org/0000-0002-2686-5307
References
- Traynor BJ, Alexander M, Corr B, et al. effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population based study, 1996-2000. J Neurol Neurosurg Psychiatry. 2003;74:1258–61.
- Chiò A, Bottacchi E, Buffa C, Mutani R, Mora G. Positive positive effects of tertiary centres for amyotrophic lateral sclerosis on outcome and use of hospital facilities. J Neurol Neurosurg Psychiatry. 2006;77:948–50.
- Zoccolella S, Beghi E, Palagano G, Fraddosio A, Guerra V, Lepore V, et al. ALS multidisciplinary clinic and survival. Results from a population-based study in Southern Italy. J Neurol. 2007;254:1107–12.
- Miller RG, Jackson CE, Kasarskis EJ, England JD, Forshew D, Johnston W, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the quality standards subcommittee of the American Academy of Neurology. Neurology 2009;73:1218–26.
- Andersen PM, Abrahams S, Borasio GD, de Carvalho M, Chio A, Van Damme P, et al. EFNS guidelines on the Clinical Management of Amyotrophic Lateral Sclerosis (MALS)-revised report of an EFNS task force. Eur J Neurol. 2012;19:360–75. Mar
- Steen IVD, Berg JPVD, Buskens E, Lindeman E, Van Den Berg LH. The costs of amyotrophic lateral sclerosis, according to type of care. Amyotroph Lateral Scler 2009;10:27–34.
- Connolly S, Heslin C, Mays I, Corr B, Normand C, Hardiman O. Health and social care costs of managing amyotrophic lateral sclerosis (ALS): an Irish perspective. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16:58–62.
- Deloitte Access Economics. Economic analysis of motor neurone disease in Australia, report for Motor Neurone Disease Australia, Deloitte Access Economics, Canberra, November. 2015. Available at: http://www.mndaust.asn.au/Influencing-policy/Economic-analysis-of-MND-(1)/Economic-analysis-of-MND-in-Australia.aspx. Accessed March 30, 2017.
- Boylan K, Levine T, Lomen-Hoerth C, Lyon M, Maginnis K, Callas P, et al. Prospective study of cost of care at multidisciplinary ALS centers adhering to American Academy of Neurology (AAN) ALS practice parameters. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 2016;17:119–27.
- Song H, Liu JC, Cao ZP, Luo WJ, Chen JY. Medical cost and healthcare utilisation of amyotrophic lateral sclerosis in China: a cohort study based on hospital data from 2015 to 2018. Medicine. 2020;99:e23258.
- Lopez-Bastida J, Perestelo-Perez L, Monton-Alvarez F, Serrano-Aguilar P, Alfonso-Sanchez JL. Social economic costs and health-related quality of life in patients with amyotrophic lateral sclerosis in Spain. Amyotroph Lateral Scler 2009;10:237–43.
- Buntin MB, Zaslavsky AM. Too much ado about two-part models and transformation? Comparing methods of modeling Medicare expenditures. J Health Econ. 2004;23:525–42.
- Manning WG, Basu A, Mullahy J. Generalized modeling approaches to risk adjustment of skewed outcomes data. J Health Econ. 2005;24:465–88.
- French EB, McCauley J, Aragon M, Bakx P, Chalkley M, Chen SH, et al. End-of-life medical spending in last twelve months of life is lower than previously reported. Health Affairs. 2017;36:1211–7.
- Meng L, Bian A, Jordan S, Wolff A, Shefner JM, Andrews J. Profile of medical care costs in patients with amyotrophic lateral sclerosis in the Medicare programme and under commercial insurance. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 2018;19:134–42.
- Van den Berg JP, Kalmijn S, Lindeman E, Veldink JH, de Visser M, Van der Graaff MM, et al. Multidisciplinary ALS care improves quality of life in patients with ALS. Neurology 2005;65:1264–7.